Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)

Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)

Dengue virus (DENV) is the most prevalent mosquito-borne viral illness in humans. Currently, there are no therapeutic agents available to prevent or treat DENV infections. Our objective was to fill this unmet medical need by evaluating the antiviral activity of interferon-α (IFN) and ribav...

Full description

Bibliographic Details
Main Authors:	Camilly P. Pires de Mello, George L. Drusano, Jaime L. Rodriquez, Ajeet Kaushik, Ashley N. Brown
Format:	Article
Language:	English
Published:	MDPI AG 2018-06-01
Series:	Viruses
Subjects:	Dengue virus antiviral therapy combination therapy ribavirin interferon-α hollow fiber infection model mathematical modeling
Online Access:	http://www.mdpi.com/1999-4915/10/6/317

Similar Items

Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study
by: Hui Li, et al.
Published: (2021-03-01)

Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice
by: Luisa Cavalletto, et al.
Published: (2008-01-01)

The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C
by: Matern Siegfried, et al.
Published: (2004-02-01)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
by: Chen Z, et al.
Published: (2017-08-01)

Evaluation of combination therapy with Interferon and Ribavirin in patients with chronic hepatitis C : a genotype based study
by: Y. Bafandeh, et al.
Published: (2007-01-01)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
by: Yasser K. Rashed, et al.
Published: (2020-02-01)

Interferon-ribavirin therapy for chronic hepatitis C: Efficacy in Saudi patients
by: Sandokji Abdulkareem, et al.
Published: (2003-01-01)

Molde brônquico devido ao uso de interferon peguilado e ribavirina Bronchial casts attributed to the use of pegylated interferon and ribavirin
by: Eduardo Garcia, et al.
Published: (2009-07-01)

Antiviral therapy of chronic hepatitis C: 30 years success story
by: D T Abdurakhmanov, et al.
Published: (2019-11-01)

Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis
by: Koichi Hashimoto, et al.
Published: (2021-01-01)

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.

Therapy with interferon-a plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Lopes Edmundo P.A., et al.
Published: (2003-01-01)

Retinal Changes In Patients with Hepatitis C Virus under treatment with interferon and ribavirin.
by: Mansour Hassan, et al.
Published: (2020-01-01)

Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
by: Jennifer Mayor, et al.
Published: (2021-06-01)

Hematological Side Effects During Combination Therapy With Interferon and Ribavirin In Chronic Hepatitis C
by: Komal Owais
Published: (2015-06-01)

Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
by: Aline Gonzalez Vigani, et al.

The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis
by: Liu Jun-Ying, et al.
Published: (2012-09-01)

Ocular manifestations in Egyptian children with chronic hepatitis C treated with pegylated interferon and ribavirin
by: Dalia H.A.R Khalil, et al.
Published: (2016-01-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

A Comparison of Interferon-Alpha-2b Induction Therapy with Interferon-Alpha-2b Plus Ribavirin Combination Therapy for the Treatment of Chronic Hepatitis C
by: Bilgehan AYGEN, et al.
Published: (2004-09-01)

Interferon alpha-2b and ribavirin as combined therapy for chronic hepatitis C in Cuba: National Program
by: Hugo Nodarse-Cuní, et al.

Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus
by: Evelyn J. Franco, et al.
Published: (2021-04-01)

Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
by: Luis Jesuino de Oliveira Andrade, et al.

Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin: a review
by: Luis Jesuíno de Oliveira Andrade, et al.

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015-05-01)

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b
by: Jovanović-Ćupić Snežana, et al.
Published: (2014-01-01)

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin
by: M.H.P. Pavan, et al.

Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users
by: Ružić Maja, et al.
Published: (2010-01-01)

Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C
by: Hamid Kalantari, et al.
Published: (2007-08-01)

Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
by: Sergio Sabbatani, et al.

Increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy
by: Shin-Yu Lu, et al.
Published: (2009-12-01)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020-07-01)

Synthesis of ribavirin 2’-Me-C-nucleoside analogues
by: Fanny Cosson, et al.
Published: (2017-04-01)

Ribavirin and its analogs: Сan you teach an old dog new tricks?
by: M. V. Chudinov
Published: (2019-08-01)

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01)

Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin
by: Kleber Prado, et al.

Lymph node enlargement during combination therapy for chronic hepatitis C with pegylated interferon alpha and ribavirin: harmless reaction or harmful disease?
by: M Wilhelmi, et al.
Published: (2006-01-01)

Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC)
by: Gupta Rahul, et al.
Published: (2012-03-01)

ORIGINAL PAPER <br>Combined interferon-alpha-2b and ribavirin therapy in patients with recurring chronic hepatitis C (genotype 1) following liver transplantation in Hungary
by: Gabriella Lengyel, et al.
Published: (2005-04-01)

Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study
by: Ružić Maja, et al.
Published: (2017-01-01)